In patients with HCC, a loss of SHP2 expression was associated with suppressed NF-κB–SHP2–ERK pathway activity and accelerated HCC development, whereas SHP2 overexpression in parallel with increased STAT3 activity was associated with fibrosis promotion during the early stages of HCC development. The gene discussed is STAT3; the disease is hepatocellular carcinoma.